secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIFECORE BIOMEDICAL, INC. DE (LFCR)
CIK:        0001005286
Form:       8-K
Filed at:   2024-08-26T23:59:59+00:00
Accession:  0001005286-24-000125
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lifecore reports FY 2024 revenue $128.3M (+24.2%), Adj. EBITDA $20.2M; FY25 rev guidance $126.5-130M
--------------------------------------------------------------------------------

- FY 2024 revenue $128.3M (+24.2% YoY); Q4 revenue $37.9M (+21.6% YoY).
- FY 2024 net income $9.3M (incl. $39.5M non-cash gain) vs loss $64.2M; Adj. EBITDA $20.2M.
- Q4 net loss $7.1M vs $37.0M (prior yr had $23.7M debt extinguish loss); Adj. EBITDA $10.4M.
- FY 2025 guidance: rev $126.5-130M, Adj. EBITDA $19-21M, capex $10-14M.
- 5-head isolator filler GMP-ready Sept 2024; headcount reduced in July; SEC filings current.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1005286/000100528624000125/0001005286-24-000125-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1005286/000100528624000125/lndc-20240826.htm
  HTML page:      https://secwatch.observer/filing/0001005286-24-000125

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer